AOD-9604 and Clopidogrel Interaction: What Women Need to Know

What Is AOD-9604 and Why Are Women Using It?

AOD-9604 is a synthetic peptide fragment corresponding to amino acids 176 to 191 of human growth hormone. Researchers originally investigated it as an anti-obesity agent because it was thought to mimic the lipolytic effects of native growth hormone without stimulating IGF-1. In clinical trials conducted in the early 2000s, including the METAOD001 study, the peptide failed to demonstrate statistically significant weight loss over placebo at any dose tested in obese adults. The FDA has never approved AOD-9604 for any indication.

Despite that history, AOD-9604 circulates widely in the peptide optimization and weight-loss space. Women in perimenopause and postmenopause, where visceral fat redistribution accelerates as estrogen declines, are a notable consumer group. Some compounding pharmacies dispense it under 503A as a subcutaneous injectable for "adipose modulation," though the FDA has questioned whether it qualifies as a bulk substance for compounding.

What the Research Actually Shows

The largest human data come from an oral AOD-9604 trial published in the International Journal of Obesity, which enrolled 300 obese men and women over 12 weeks. Weight loss was not significantly different from placebo. No study has evaluated subcutaneous AOD-9604 for weight loss in a randomized controlled trial published in a peer-reviewed journal. The evidence base for the formulation most women are actually using is, put plainly, almost nonexistent.

Women-Specific Context

Women with PCOS, hypothyroidism-related weight gain, or postmenopausal metabolic shift are the populations most likely to seek out AOD-9604. These are the same populations who may also carry cardiovascular risk factors that lead to clopidogrel prescriptions. That overlap is why the interaction question matters clinically.

How Clopidogrel Works: The CYP2C19 Pathway

Clopidogrel is an oral thienopyridine antiplatelet agent. It is a prodrug. The liver must convert it to its active thiol metabolite via CYP2C19, the cytochrome P450 enzyme that accounts for the majority of its bioactivation. Once activated, clopidogrel irreversibly binds the platelet P2Y12 ADP receptor, reducing platelet aggregation for the roughly 7 to 10 days those platelets survive.

Why CYP2C19 Matters for Women

CYP2C19 activity is not uniform. Approximately 2 to 15% of people of European descent and up to 29% of some East Asian populations are CYP2C19 poor metabolizers, meaning they convert very little prodrug to active metabolite. Critically for women, estrogen and progesterone modulate hepatic CYP2C19 expression. Studies examining oral contraceptive users found that exogenous estrogen-progestin combinations can inhibit CYP2C19 activity by up to 30%, which may reduce clopidogrel's antiplatelet efficacy.

Across the menstrual cycle, endogenous estradiol peaks at mid-cycle and again in the mid-luteal phase. No large trial has mapped clopidogrel pharmacokinetics to menstrual cycle phase, which is a genuine evidence gap you deserve to know about. Postmenopausal women who are not on hormone therapy lose the cyclical estrogen influence on CYP2C19, but may have other metabolic changes that shift enzyme activity. The FDA label for clopidogrel (Plavix) does not stratify pharmacokinetic data by sex or hormonal status, which reflects a longstanding gap in cardiovascular trial design.

The Poor-Metabolizer Problem in Women

If you are a CYP2C19 poor metabolizer and you are prescribed clopidogrel after a coronary stent, you may not be getting adequate platelet inhibition. The TRITON-TIMI 38 trial showed that patients with loss-of-function CYP2C19 alleles had a 53% higher rate of cardiovascular death, heart attack, or stroke compared with non-carriers on clopidogrel. Sex-stratified data from that trial were not prominently reported, which is the kind of evidence gap WomanRx flags explicitly.

The AOD-9604 and Clopidogrel Interaction: What the Data Say

No published pharmacokinetic study has directly examined AOD-9604 co-administration with clopidogrel. That absence of data is itself the most important clinical fact here. It does not mean the interaction is safe. It means no one has looked.

Theoretical Pharmacokinetic Pathways

AOD-9604, as a peptide, is expected to be metabolized by proteases in plasma and tissue rather than through hepatic cytochrome P450 enzymes. If that expectation holds, AOD-9604 would not directly compete with clopidogrel for CYP2C19 conversion, and there may be no pharmacokinetic drug-drug interaction in the classical sense.

However, three caveats apply.

First, the metabolic fate of subcutaneous AOD-9604 in humans has not been rigorously characterized in peer-reviewed literature. Assuming peptide-only clearance is an extrapolation, not a measured fact.

Second, pharmacodynamic interaction is a separate question from pharmacokinetic interaction. If AOD-9604 has any direct or indirect effect on platelet function, coagulation factors, or endothelial nitric oxide production, it could add to or subtract from clopidogrel's antiplatelet effect regardless of CYP2C19. The FDA's guidance on evaluating drug interactions does not include AOD-9604 in any substrate, inhibitor, or inducer table because it has never undergone formal interaction evaluation.

Third, compounded AOD-9604 preparations vary. Excipients, preservatives, and co-peptides in a compounded vial are not standardized. Any of those components could theoretically interact with clopidogrel's metabolism or platelet function, and no one has studied that either.

Severity Classification

Without a published interaction study, standard DDI databases (Lexicomp, Micromedex, Clinical Pharmacology) carry no entry for this combination. That means the severity is formally "unknown," not "none." An unknown severity with a narrow-therapeutic-window antiplatelet drug in a patient whose cardiovascular status depends on reliable P2Y12 inhibition is a clinically meaningful risk that warrants caution.

The WomanRx Clinical Risk Framework for uncharacterized peptide-plus-antiplatelet combinations assigns a precautionary amber classification: not confirmed dangerous, not confirmed safe, requires prescriber-level conversation before use. The three elements that push a combination into amber rather than green are: (1) the antiplatelet drug has a narrow effective range where under-inhibition means thrombosis and over-inhibition means bleeding, (2) the peptide's pharmacodynamic effects on hemostasis are unknown, and (3) the patient population includes life-stage variables (hormonal status, OCP use) that alter the CYP2C19 pathway relevant to the antiplatelet.

Bleeding Risk: What Women Should Watch For

Clopidogrel's primary harm is bleeding. The CAPRIE trial, the foundational efficacy study for clopidogrel, reported a severe bleeding rate of 1.4% per year. Any agent that augments platelet inhibition beyond the therapeutic window raises that rate.

For women, there are two bleeding scenarios that male-default cardiovascular literature often underemphasizes.

Menstrual and Uterine Bleeding

Women of reproductive age on clopidogrel may already experience heavier menstrual periods. Adding any agent with unknown platelet effects could worsen menorrhagia. Women with fibroids, adenomyosis, or a history of heavy menstrual bleeding are at particular risk. If you notice your period becoming significantly heavier after starting AOD-9604, that is a signal to stop and contact your clinician before your next dose.

Postmenopausal Vaginal or Uterine Bleeding

Postmenopausal women on clopidogrel who develop any new vaginal bleeding face a dual diagnostic challenge: ruling out endometrial pathology while also accounting for antiplatelet-related mucosal fragility. Adding an uncharacterized peptide to that picture makes clinical assessment harder, not easier.

Monitoring Checklist

• Complete blood count with platelets at baseline and at 4 to 6 weeks if you choose to use both agents under clinician supervision
• Platelet function assay (VerifyNow P2Y12) if available, to confirm clopidogrel is still providing adequate inhibition
• Track menstrual cycle blood loss with a validated tool such as the Pictorial Blood Assessment Chart
• Report any bruising, prolonged bleeding from minor cuts, blood in urine or stool, or severe headache immediately

Who This Combination Is Not Right For

The following groups should not use AOD-9604 while taking clopidogrel unless a prescribing clinician with full access to their cardiovascular history has reviewed and approved the combination.

Post-stent women. If you had a coronary or peripheral stent placed and clopidogrel is part of your dual antiplatelet therapy, any disruption of clopidogrel's efficacy, or any added bleeding risk, can be life-threatening. Stent thrombosis is a medical emergency. The ACC/AHA guidelines on dual antiplatelet therapy provide duration recommendations that assume the antiplatelet drug is working as labeled.

Women with a history of stroke or TIA. Clopidogrel is frequently used for secondary stroke prevention. Anything that might reduce its efficacy or increase bleeding into brain tissue represents unacceptable uncharacterized risk.

Perimenopausal women with combined cardiovascular risk. The perimenopausal window, roughly age 45 to 55, is when cardiovascular risk rises sharply as estrogen declines. Women in this stage who are on clopidogrel are, by definition, already managing significant vascular disease. Adding an unregulated injectable peptide without clinical supervision is not appropriate.

Women on combined oral contraceptives. OCP-related CYP2C19 inhibition may already blunt clopidogrel's bioactivation. Adding AOD-9604 on top of that pharmacological milieu creates compounding unknowns.

Who Might Cautiously Discuss This With a Clinician

Women who are using AOD-9604 for research purposes only, have no active cardiovascular indication for clopidogrel, and whose clinician has reviewed the full picture may have a lower risk profile. Even so, because AOD-9604 is not FDA-approved, has no established dosing standard, and is dispensed through compounding pharmacies where batch-to-batch consistency is not guaranteed, the appropriate step is always a prescriber conversation first.

If you are on clopidogrel for any cardiovascular reason and are considering any new injectable peptide, bring the actual vial or compounding pharmacy receipt to your appointment. Your clinician needs to see exactly what is in the formulation.

Pregnancy, Lactation, and Contraception

This section is required for any drug article on WomanRx and reflects the most critical safety guidance.

AOD-9604 in Pregnancy

AOD-9604 has no pregnancy safety data in humans. None. The peptide has never been studied in pregnant women in any published trial. Animal reproductive toxicity studies are not available in the peer-reviewed literature. Because it is a fragment of growth hormone, and because growth hormone axis disruption during fetal development carries theoretical teratogenic risk, use during pregnancy cannot be considered safe by any reasonable clinical standard.

If you are trying to conceive, you should stop AOD-9604 before attempting pregnancy. The washout period is not established because human pharmacokinetic data are incomplete, but given its peptide nature and likely short half-life, a minimum of 30 days pre-conception washout is a reasonable precautionary standard in the absence of better data.

Clopidogrel in Pregnancy

Clopidogrel is FDA Pregnancy Category B, meaning animal studies showed no harm but adequate human data are absent. Real-world case series suggest clopidogrel use near delivery increases the risk of maternal hemorrhage and may cause fetal platelet inhibition. ACOG advises that antiplatelet agents other than low-dose aspirin should be used in pregnancy only when the maternal cardiovascular benefit clearly outweighs fetal risk, and the decision should involve maternal-fetal medicine consultation.

Women with mechanical heart valves or high thrombotic risk who cannot discontinue clopidogrel represent a narrow exception managed by specialists.

Lactation

Clopidogrel transfer into breast milk has not been systematically studied in humans. Because of the potential for platelet inhibition in a nursing infant, most guidelines recommend avoiding clopidogrel during lactation unless no safer alternative exists. AOD-9604 lactation transfer data are nonexistent.

If you are breastfeeding and on clopidogrel, discuss the risk-benefit ratio with your cardiologist and your obstetric provider together. Do not add AOD-9604 while breastfeeding.

Contraception Requirements

Neither agent has a formalized contraception requirement in the way that teratogens like isotretinoin do. But the practical guidance is clear. If you are of reproductive age, using AOD-9604 for any reason, and on clopidogrel for a cardiovascular indication, use reliable contraception. An unplanned pregnancy on both agents would require urgent specialist review. The combined contraceptive pill adds CYP2C19 complexity (as described above), so discuss IUD, barrier, or progestin-only options with your prescriber.

What to Tell Your Doctor Before Combining These Agents

Bring these specific questions to your appointment.

First, ask whether your clopidogrel indication is still the right drug choice given your current CYP2C19 genotype status. If you have never been genotyped, ask whether pharmacogenomic testing is appropriate for you.

Second, tell your prescriber you are considering or already using AOD-9604, the dose and frequency, and the name of the compounding pharmacy. Clinicians cannot assess risk they do not know about.

Third, ask about alternative weight-management options with an actual evidence base. FDA-approved GLP-1 receptor agonists such as semaglutide have published cardiovascular outcome trial data, including in the SELECT trial, which showed a 20% reduction in major adverse cardiovascular events in overweight adults without diabetes. That is a drug with a real evidence base that your cardiologist and weight-management team can evaluate together.

AOD-9604 Drug Interactions: The Broader Picture

The clopidogrel question is the most clinically pressing for women on antiplatelet therapy, but AOD-9604's interaction profile with other drugs is equally uncharacterized. No formal drug-drug interaction studies have been published. The absence of CYP involvement (assumed, not proven) means classical interaction screening tools may not catch problems.

Women taking any of the following should flag AOD-9604 to their prescriber before using it.

• Warfarin or direct oral anticoagulants (DOACs): any platelet or coagulation effect from AOD-9604 could shift bleeding risk unpredictably
• NSAIDs used regularly for pain conditions like endometriosis: combined platelet effects are possible
• Metformin or other metabolic agents: pharmacodynamic overlap in glucose or lipid pathways cannot be excluded based on AOD-9604's original mechanism hypothesis
• Thyroid medications: women with hypothyroidism who are dose-optimized on levothyroxine could theoretically see shifts in metabolic rate if AOD-9604 has any actual lipolytic or metabolic effect, though this is entirely speculative given the limited human data

The honest answer to "what are AOD-9604's drug interactions?" is that we do not know, because the drug was never brought through the full FDA approval pathway that requires this testing.

A Note on the Evidence Gap for Women

Women have been systematically underrepresented in cardiovascular drug trials for decades. The National Institutes of Health Revitalization Act of 1993 mandated inclusion of women and minorities in federally funded research, but implementation has been uneven. The original clopidogrel trials enrolled predominantly male cohorts. Peptide research compounds like AOD-9604 have no sex-stratified data at all.

This means that when you ask your doctor about AOD-9604 and clopidogrel, the honest answer is not that the combination has been proven safe in women or that it has been proven dangerous. The honest answer is that women's bodies were not part of the research that would let anyone give you a confident answer. That gap should make you more cautious, not less.